Compare WSBF & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WSBF | DCTH |
|---|---|---|
| Founded | 1921 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 336.0M | 311.7M |
| IPO Year | 2013 | 2015 |
| Metric | WSBF | DCTH |
|---|---|---|
| Price | $18.34 | $9.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $22.00 |
| AVG Volume (30 Days) | 65.5K | ★ 297.5K |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | 46.53 | ★ 107.53 |
| EPS | ★ 1.48 | 0.07 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $24.54 |
| Revenue Next Year | N/A | $33.15 |
| P/E Ratio | ★ $12.30 | $137.57 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.61 | $8.12 |
| 52 Week High | $18.88 | $18.23 |
| Indicator | WSBF | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 59.57 | 56.79 |
| Support Level | $16.90 | $8.90 |
| Resistance Level | $18.62 | $10.17 |
| Average True Range (ATR) | 0.38 | 0.30 |
| MACD | 0.03 | 0.07 |
| Stochastic Oscillator | 74.87 | 77.50 |
Waterstone Financial Inc is a holding company. Through its subsidiaries, it operates in two reportable segments: Community Banking and Mortgage Banking. The Community Banking segment provides consumer and business banking products and services to customers, which include various types of loans, deposits, and personal investment services. The Mortgage Banking segment involves residential mortgage loans for the primary purpose of sale in the secondary market. The majority of its revenue comes from the Community Banking segment.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.